N/A N=100 Psychosis: Early Detection, Intervention and Prevention
Prodromal Schizophrenia · Psychotic Disorders · Severe Bipolar Disorder With Psychotic Features
Primary: Onset of Psychosis — 10; 14 percentage of sample converting
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=323 An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…
Phase 4 N=60 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
Phase 4 N=80 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale
N/A N=165 Biomarkers in First Episode Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder, Depressed Type
Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
N/A N=63 Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia
Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale
N/A N=14 First Episode Schizophrenia and Cannabis-Related Disorder Study
Cannabis-Related Disorder · Substance-Related Disorders · Schizophrenia
Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
N/A N=538 Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes
Schizophrenia
Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001
Phase 1 N=37 A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Abbreviated Extrapyramidal Symptom Rating Scale (ESRS-A) Scores (Cohorts 1 and 2) at Day 10 — -0.2; -0.3; 0.1; 0.0 Units on a scale
N/A N=88 Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30
Phase 4 N=491 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
Schizophrenia
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…
Phase 2 N=245 A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -9.7; -17.2 Units on a scale — p=0.001
Phase 2 N=40 Fingolimod in Schizophrenia Patients
Schizophrenia
Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms
N/A N=103 USS Training to Improve Social Function in People With Psychosis
Psychosis
Primary: Social Functioning Scale (SFS) Change — 1.28; 0.19; 1.56; 0.32 score on a scale
N/A N=176 Brief Group Psychoeducation for Schizophrenia
Schizophrenia
Primary: Number of Participants With Relapse — 22; 23 Participants — p=0.59
N/A N=14 Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
Schizophrenia
Primary: Change in BOLD Signal in Anterior Cingulate Cortex — -0.0188; 0.0124 BOLD signal change (Mismatch vs. Match)
Phase 3 N=463 A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Schizophrenia
Primary: Change From Baseline in PANSS Total Score at Week 6 — -19.3; -16.9; -19.6 score on a scale — p=0.886
Phase 2 N=51 Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
Phase 1 N=22 A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
Schizophrenia
Primary: Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA. — -0.0007; -0.0008; -0.0006; -0.0008 Kicer — p=0.0072
Phase 4 N=75 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
Schizophrenia
Primary: Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52 — 50.65; 58.71; 5.35; 5.96 units on a scale — p=0.8595
N/A N=69 Cognitive Training for Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder · Other Primary Psychotic Disorders
Primary: UCSD Performance-based Skills Assessment Total Score (Measures Functional Capacity) — 82.7; 84.4 units on a scale
Phase 3 N=386 To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia
Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses
N/A N=17 Oxytocin Treatment of Schizophrenia
Paranoia · Schizophrenia · Schizoaffective Disorder
Primary: Emotion Recognition as Measured by the Emotion Recognition-40 at the 6 Week Time Point — 7.25; 6.67; 4.38; 6.17 number of correct responses — p=.61
Phase 2 N=60 A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
Schizophrenia
Primary: Change in Positive and Negative Syndrome Scale (PANSS) - Total Score - Study Phases 1 and 2 — 83.6; 79.8; 77.6; 76.7 units on a scale — p=0.57
Phase 1 N=71 Metabolic Signatures and Biomarkers in Schizophrenia
Schizophrenia
Primary: Total Plasmalogen Levels in the Lipid Profile — 57.65; 59.57; 75 nmoles/gram — p=0.0149
N/A N=24 rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia
Schizophrenia
Primary: Change in Precuneus Functional Activation — 0.0329; 0.067; -0.010 Beta coefficient change (Target vs Foil) — p=0.32
N/A N=20 Clinical Trial of Dipyridamole in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale
Phase 2 N=334 Study of a Novel Antipsychotic ITI-007 in Schizophrenia
Schizophrenia
Primary: Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score — -13.2; -8.3; -7.4; -13.4 score on a scale — p=0.017